Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines (Q39403005)

11 September 2017

title

Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines (English)

1 reference

11 September 2017

K Frenzel

1

1 reference

11 September 2017

S Ganepola

2

1 reference

11 September 2017

D Michel

3

1 reference

11 September 2017

E Thiel

4

1 reference

11 September 2017

D H Krüger

5

1 reference

11 September 2017

L Uharek

6

1 reference

11 September 2017

J Hofmann

7

1 reference

11 September 2017

publication date

1 August 2012

1 reference

Medical Microbiology and Immunology

11 September 2017

published in

1 reference

11 September 2017

volume

201

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

277-286

1 reference

How we treat cytomegalovirus in hematopoietic cell transplant recipients

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Human cytomegalovirus DNA replication: antiviral targets and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Regression of fetal cerebral abnormalities by primary cytomegalovirus infection following hyperimmunoglobulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Human cytomegalovirus hyperimmune globulin not only neutralizes HCMV infectivity, but also inhibits HCMV-induced intracellular NF-kappaB, Sp1, and PI3-K signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

High genotypic diversity and a novel variant of human cytomegalovirus revealed by combined UL33/UL55 genotyping with broad-range PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Cytomegalovirus evasion of innate immunity by subversion of the NKR-P1B:Clr-b missing-self axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0229-2

Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations

21 January 2018

1 reference

12 December 2020

Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H

1 reference

12 December 2020

Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients

1 reference

12 December 2020

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

1 reference

12 December 2020

The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection

1 reference

12 December 2020

CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.

1 reference

12 December 2020

Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response

1 reference

12 December 2020

Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis

1 reference

12 December 2020

Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters

1 reference

12 December 2020

Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation

1 reference

12 December 2020

Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infecti

1 reference

12 December 2020

Strain-specific neutralization of human cytomegalovirus isolates by human sera.

1 reference

12 December 2020

Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection

1 reference

12 December 2020

10.1007/S00430-012-0229-2

Identifiers

DOI

1 reference

11 September 2017

1 reference